Drug Price Trends for INSULIN GLARGINE

Average Pharmacy Cost for INSULIN GLARGINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
INSULIN GLARGINE SOLOSTAR U300	00955-3900-03	36.66702	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 PEN	83257-0015-32	5.93498	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 VL	49502-0393-80	6.09673	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 PEN	49502-0394-75	5.93498	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 VL	83257-0014-11	6.09673	ML	2025-03-19

Insulin Glargine Market Analysis and Price Projections

Market Size and Growth Projections

The insulin glargine market is poised for significant growth over the coming years, driven by several key factors. As of 2024, the market size is estimated to be around USD 1.54 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.28% to reach USD 2.09 billion by 2029[1].

By 2033, the global insulin glargine market is anticipated to exceed USD 2.50 billion, growing at a CAGR of 6.12% from 2023 to 2033[3]. Another forecast suggests that the market will reach USD 2200 million by 2031, with a CAGR of 6.11% during the period from 2023 to 2031[4].

Key Drivers of Market Growth

Increasing Prevalence of Diabetes

The global increase in the prevalence of both Type 1 and Type 2 diabetes is a major driver of the insulin glargine market. The sedentary lifestyle and other lifestyle factors have contributed to a surge in diabetic cases, particularly in developed countries[3][4].

Advancements in Insulin Formulations

Advancements in insulin formulations, especially the development of long-acting basal insulin analogs like glargine, have improved glycemic control. These formulations offer predictable absorption and reduced risk of hypoglycemia, making them preferred choices among physicians and patients[3].

Growing Geriatric Population

The growing geriatric population, especially in developed countries, is another significant factor. Older adults are more prone to developing diabetes, which increases the demand for insulin glargine[3].

Expansion in Emerging Markets

Improving healthcare infrastructure and rising disposable incomes in emerging markets have also contributed to the increased penetration and demand for insulin glargine[3].

Market Segmentation

The global insulin glargine market is segmented by type and geography. The types include Lantus, Basaglar, Toujeo, Soliqua/Suliqua, and insulin glargine biosimilars. Geographically, the market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa[1].

Regional Market Analysis

• North America: This region holds the largest market share and is expected to grow at the highest CAGR during the forecast period. The significant prevalence of diabetes in the United States, primarily due to sedentary lifestyles, drives this market[1][4].
• Asia-Pacific: This region is expected to grow rapidly due to the increasing prevalence of diabetes and improving healthcare infrastructure[3].

Major Players and Market Competition

The global insulin glargine market is moderately consolidated, with major players such as Sanofi, Novo Nordisk, Biocon, Eli Lilly and Company, and Julphar dominating the market. These companies have established strong supply chains and branding, which has resulted in substantial market penetration[1].

Strategic Alliances and Product Developments

Companies like Eli Lilly and Boehringer Ingelheim have formed alliances to develop and commercialize products like Basaglar (insulin glargine), while Biocon has collaborated with Mylan to develop Semglee (an insulin glargine biosimilar)[1].

Price Projections and Cost Analysis

Current Market Prices

The current market prices of insulin glargine are significantly higher than the estimated cost-based prices. For instance, basal-bolus treatment with insulin glargine and aspart could cost around $111 per year, which is far above the estimated cost-based prices[2].

Cost-Based Price Estimates

Studies suggest that insulins, including insulin glargine, can be manufactured at much lower costs than current market prices. Estimated cost-based prices per month for insulin glargine could range from $0.75 to $72.49, which is substantially lower than current market prices[2].

Recent Price Adjustments

Sanofi has recently announced a 78% reduction in the list price of Lantus (insulin glargine injection) in the U.S. and capped out-of-pocket costs at $35 for all patients with commercial insurance. This move aims to make insulin more affordable and accessible[5].

Impact of COVID-19

The COVID-19 pandemic has resulted in a surge in diabetic complexities, further driving the demand for insulin in the market. Patients with diabetes are at a higher risk of hospitalization and incur more healthcare expenses, which has accelerated the need for effective diabetes management solutions like insulin glargine[1].

Key Takeaways

• The insulin glargine market is expected to grow significantly, driven by the increasing prevalence of diabetes and advancements in insulin formulations.
• North America is the largest market and is expected to grow at the highest CAGR.
• Major players like Sanofi, Novo Nordisk, and Eli Lilly dominate the market through strategic alliances and product developments.
• There is a significant gap between current market prices and estimated cost-based prices, highlighting potential for cost reduction.
• Recent price adjustments by companies like Sanofi aim to make insulin more affordable.

FAQs

What is the projected market size of the insulin glargine market by 2029?

The insulin glargine market is expected to reach USD 2.09 billion by 2029, growing at a CAGR of 6.28% from 2024 to 2029[1].

Which region is the largest market for insulin glargine?

North America is the largest market for insulin glargine and is expected to grow at the highest CAGR during the forecast period[1][4].

Who are the major players in the insulin glargine market?

The major players include Sanofi, Novo Nordisk, Biocon, Eli Lilly and Company, and Julphar[1].

What are the estimated cost-based prices for insulin glargine compared to current market prices?

Estimated cost-based prices for insulin glargine are significantly lower than current market prices, ranging from $0.75 to $72.49 per month[2].

How has the COVID-19 pandemic impacted the insulin glargine market?

The COVID-19 pandemic has resulted in a surge in diabetic complexities, driving the demand for insulin glargine and other diabetes management solutions[1].

Sources

1. Mordor Intelligence, "Insulin Glargine Market - Size & Share - Mordor Intelligence"
2. JAMA Network, "Estimated Sustainable Cost-Based Prices for Diabetes Medicines"
3. Spherical Insights, "Global Insulin Glargine Market Size, Growth, Forecasts to 2033"
4. Straits Research, "Insulin Glargine Market Size to Reach 2200 Million by 2031"
5. Sanofi, "Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance"